Abstracts Archive - Page 880 of 2425 - ACR Meeting Abstracts

Abstract Number: 1824 • 2019 ACR/ARP Annual Meeting
Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Sarah Patterson¹, Laura Trupin ¹, Cristina Lanata ¹, Louise Murphy ², Wendy Hartogenesis ¹, Maria Dall'Era ¹, Jinoos Yazdany ³ and Patricia Katz ¹, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A new posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the division of symptomatology into two groups: type 1 manifestations represent…
Abstract Number: 1825 • 2019 ACR/ARP Annual Meeting
Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis
Michelle Petri¹, Jessica Li ¹, John Conklin ², Tyler O'Malley ³, Jo-Anne Ligayon ², Leilani Wolover ² and Thierry Dervieux ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA
Background/Purpose: We previously developed a Thrombosis Risk Score, a sum of three factors: lupus anticoagulant (by RVVT confirm); low C3; and C4d bound to platelets.…
Abstract Number: 1826 • 2019 ACR/ARP Annual Meeting
Describing Intra-Individual Cognitive Function Course over Time in Lupus Patients: Persistent and Fluctuating Cognitive Impairment, Affected Cognitive Domains, and Severity
Oshrat Tayer-Shifman¹, Dorcas Beaton ², Robin Green ³, Lesley Ruttan ³, Joan Wither ⁴, Maria Tartaglia ⁵, Mahta Kakvan ¹, Sabrina Lombardi ³, Nicole Anderson ¹, Jiandong Su ¹, Dennisse Bonilla ¹, Moe Zandy ¹, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²St. Michael's Hospital, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Cognitive impairment (CI) is a common manifestation of systemic lupus erythematosus (SLE). The course of CI in SLE patients has been described as persistent…
Abstract Number: 1827 • 2019 ACR/ARP Annual Meeting
Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus
Stanley Moore ¹, Hsin-Hsuan Juo ¹, Christoffer Nielsen ², Helena Tyden ³, Anders Bengtsson ³ and Christian Lood¹, ¹University of Washington, Seattle, ²Statens Serum Institut, Copenhagen, Denmark, ³Lund University, Lund, Sweden
Background/Purpose: Neutrophil activation, including formation of neutrophil extracellular traps (NETs), is essential in host defense. However, NET formation has also been linked to inflammation and…
Abstract Number: 1828 • 2019 ACR/ARP Annual Meeting
Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus
Kevin Yip¹, Elizaveta Efuni ², Yingzhi Qian ¹, Robert Clancy ³, Jill Buyon ² and Ashira Blazer ¹, ¹New York University School of Medicine, New York City, ²New York University School of Medicine, New York, NY, ³New York University School of Medicine, New York
Background/Purpose: African Americans (AA) with systemic lupus erythematous (SLE) are at higher risk for both renal disease and avascular necrosis (AVN). The two Apolipoprotein L1…
Abstract Number: 1829 • 2019 ACR/ARP Annual Meeting
Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients
Melissa E. Munroe¹, Sarah Kleckner ¹, Wade DeJager ¹, Susan R. Macwana ¹, Joel Guthridge ², Eldon Jupe ³, Mohan Purushothaman ³, Sanjiv Sharma ³, Nancy Redinger ¹, Teresa Aberle ¹, Stan Kamp ¹, Cristina Arriens ², Eliza F. Chakravarty ², Joan T. Merrill ⁴ and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is marked by altered immune regulation linked to waxing and waning clinical disease activity. This study seeks to verify the alteration of inflammatory…
Abstract Number: 1830 • 2019 ACR/ARP Annual Meeting
Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth Volkmann¹, Virginia Steen ², Ning Li ³, Michael Roth ⁴, Philip Clements ³, Dinesh Khanna ⁵, Daniel Furst ⁶, Shervin Assassi ⁷, Grace Kim ³, Jonathan Goldin ³, Robert Elashoff ³ and Donald Tashkin ³, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²Georgetown University, Washington, D.C., USA, Georgetown, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁶University of California, Los Angeles, CA, ⁷Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX
Background/Purpose: Observational studies have demonstrated that African American (AA) patients with systemic sclerosis (SSc) have a more unfavorable prognosis compared with non-AA. However, no studies…
Abstract Number: 1831 • 2019 ACR/ARP Annual Meeting
Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes
Sarah French¹, Kim Taylor ¹, Stephanie Rush ² and Francesco Boin ¹, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA
Background/Purpose: Pulmonary disease is a leading cause of mortality in scleroderma (SSc). Previous studies indicate that the coexistence of pulmonary hypertension (PH) and interstitial lung…
Abstract Number: 1832 • 2019 ACR/ARP Annual Meeting
Reliability of Traditional Cardiovascular Risk Calculators in Predicting Risk of Cardiovascular Disease in Systemic Sclerosis
Yasser Radwan¹, Reto Kurmann ², Avneek Singh Sandhu ³, Cynthia Crowson ⁴, Eric Matteson ⁵, Thomas Osborn ¹, Kenneth Warrington ², Rekha Mankad ¹ and Ashima Makol ¹, ¹Mayo Clinic Minnesota, rochester, MN, ²Mayo Clinic Rochester, rochester, MN, ³kettering health, dayton, OH, ⁴Mayo Clinic Rochester, Rochester, ⁵Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester
Background/Purpose: Most cardiovascular (CV) risk calculators including the Framingham risk score (FRS) and American College of Cardiology (ACC) / American Heart Association (AHA) risk score…
Abstract Number: 1833 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial
Kristin Highland¹, Oliver Distler ², Masataka Kuwana ³, Yannick Allanore ⁴, Shervin Assassi ⁵, Arata Azuma ⁶, Arnaud Bourdin ⁷, Christopher Denton ⁸, Jörg Distler ⁹, Anna Maria Hoffmann-Vold ¹⁰, Dinesh Khanna ¹¹, Maureen Mayes ⁵, Ganesh Raghu ¹², Madelon Vonk ¹³, Martina Gahlemann ¹⁴, Mannaig Girard ¹⁵, Susanne Stowasser ¹⁶, Donald Zoz ¹⁷, Aryeh Fischer ¹⁸ and Toby Maher ¹⁹, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁶Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ⁷PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214 and Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, Montpellier, France, Montpellier, ⁸University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ¹⁰Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²University of Washington, Seattle, USA, Seattle, ¹³Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ¹⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹⁵Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ¹⁸University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ¹⁹National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the annual rate of decline in forced vital capacity…
Abstract Number: 1834 • 2019 ACR/ARP Annual Meeting
Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
Shervin Assassi¹, Ning Li ², Elizabeth Volkmann ³, Maureen Mayes ¹, Jun Ying ⁴, Michael Roth ⁵, Philip Clements ², Daniel Furst ⁶, Dinesh Khanna ⁷, Jonathan Goldin ², Robert Elashoff ² and Donald Tashkin ², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴University of Texas McGovern Medical School at Houston, Houston, TX, ⁵University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶University of California, Los Angeles, CA, ⁷Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Response to immunosuppression is highly variable in systemic sclerosis (SSc) related interstitial lung disease (ILD), and there are no widely accepted clinical or biological…
Abstract Number: 1835 • 2019 ACR/ARP Annual Meeting
Frequency and Predictors of Meaningful Decline in Forced Vital Capacity During Follow up оf a Large Cohort of Systemic Sclerosis Associated Pulmonary Fibrosis Patients
Svetlana Nihtyanova¹, Emma Derrett-Smith ¹, Carmen Fonseca ¹, Voon Ong ² and Christopher Denton ³, ¹UCL Medical School, Royal Free Campus, London, United Kingdom, ²UCL Medical School, Royal Free Campus, London, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Pulmonary fibrosis (PF) is common in systemic sclerosis (SSc) and serial pulmonary function tests (PFTs) are used for routine PF monitoring. Forced vital capacity…
Abstract Number: 1836 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
Robert Spiera¹, Sebastian Unizony ², Min Bao ³, Yves Luder ⁴, Páris Sidiropoulos ³, Jian Han ³, Jinglan Pei ³ and John Stone ², ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Genentech, South San Francisco, CA, ⁴F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: GiACTA, a randomized, double-blind, placebo (PBO)–controlled study, demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA).1 Growing evidence…
Abstract Number: 1837 • 2019 ACR/ARP Annual Meeting
Ustekinumab for the Treatment of Giant Cell Arteritis
Mark Matza¹, John Stone ¹, Ana Fernandes ¹ and Sebastian Unizony ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Disease flare despite high cumulative glucocorticoid exposure is one of the hallmarks of giant cell arteritis (GCA). Tocilizumab is effective in controlling disease activity…
Abstract Number: 1838 • 2019 ACR/ARP Annual Meeting
Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial
John Stone¹, Helen Spotswood ², Sebastian Unizony ¹, Martin Aringer ³, Daniel Blockmans ⁴, Elisabeth Brouwer ⁵, Maria C. Cid ⁶, Bhaskar Dasgupta ⁷, Jürgen Rech ⁸, Carlo Salvarani ⁹, Robert Spiera ¹⁰ and Min Bao ¹¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁴Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Genentech, South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) administered subcutaneously every week (QW) or every other week (Q2W) with 26-week prednisone tapering was superior to placebo (PBO) plus 26-week (PBO+26)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].